Polio
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
SanofiPARIS, France
2 programsIMOVAX Polio™: Inactivated Poliomyelitis VaccinePHASE_4Vaccine1 trial
Injectable inactivated types 1, 2 and 3 poliovirus + Live oral PolioPHASE_41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SanofiInjectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio
SanofiIMOVAX Polio™: Inactivated Poliomyelitis Vaccine
Clinical Trials (2)
Total enrollment: 5,463 patients across 2 trials
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
Start: Nov 2011Est. completion: Nov 2013456 patients
Phase 4Completed
A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China
Start: Dec 2010Est. completion: Jun 20125,007 patients
Phase 4Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Vaccine is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.